Company intelligence / Profile preview

Nanoligent

Barcelona, Catalonia, Spain

Ownership: Private
Employees: ~15
Development stage: Preclinical

Overview

Nanoligent’s lead program targets the CXCR4 receptor to halt tumor growth and metastasis using a novel protein nanoparticle approach. The company has demonstrated promising preclinical results and aims to develop affordable, effective therapies with fewer side effects than traditional drugs. The technology holds potential for application beyond oncology. No published human clinical data as of May 2025.

Therapeutic areas: Oncology
Modalities: Protein conjugates/nanoparticlesTargeted drug delivery systems
Industry: Biotech

Drug pipeline

1 asset

T22-PE24-H6

Preclinical

Partnerships

i&i Biotech Fund I (investment/strategic support)

Beyond the preview

Go deeper on Nanoligent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanoligent.

Explore the full profile